Drug intelligence / Profile preview

almonertinib + pemetrexed + cisplatin

Development stage: Preclinical
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of almonertinib (a third-generation EGFR tyrosine kinase inhibitor), pemetrexed (a multitargeted antifolate cytotoxic chemotherapy agent), and cisplatin (a platinum-based chemotherapy drug). This regimen is being investigated for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). The combination aims to leverage both targeted therapy through EGFR inhibition and cytotoxic effects of chemotherapy to improve treatment outcomes.

Targets

DNAEGFR T790M (Epidermal growth factor receptor T790M mutant)DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)

Beyond the preview

Go deeper on almonertinib + pemetrexed + cisplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on almonertinib + pemetrexed + cisplatin.

Explore the full profile